Latest revenue
$150.6M
as of 2026-03-31
Latest net income
$-19.8M
as of 2026-03-31
Net margin
-13.1%
as of 2026-03-31
Community sentiment
Where do you think GKOS is heading?
Keep private notes on GKOS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
GKOS vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $7.43B
- Enterprise value
- $7.67B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 11.07×
- Dividend yield
- 0.0%
- 52-wk high
- $148.00
- 52-wk low
- $73.16
- Beta
- —
- Shares out
- 58.7M
What this company does
ITEM 1. BUSINESS Overview Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012. In 2024, we commenced commercialization activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. We…
AI summary unavailable — showing raw filing excerpt
Generated from GKOS's filing dated 2026-02-23
Key risks
Item 1A. Risk Factors The risks and uncertainties discussed below are not the only ones facing our business but do represent those risks that we believe are material to us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also harm our business. Please read the cautionary notice regarding forward-looking statements preceding Part I, Item 1 in this Annual Report. Risks Related to Our Business The commercial success of our iDose TR and Epioxa products is dependent upon multiple factors, the failure of any one of which could materially impact the prospects of these products and our business. Our iDose TR travoprost intracameral implant was…
AI summary unavailable — showing raw filing excerpt
Generated from GKOS's filing dated 2026-02-23
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.